{"id":"rexlemestrocel-l-ha-mixture","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or swelling"},{"rate":null,"effect":"Transient joint effusion"},{"rate":null,"effect":"Infection at injection site"}]},"_chembl":{"chemblId":"CHEMBL3545318","moleculeType":"Cell"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Rexlemestrocel-L consists of bone marrow-derived mesenchymal stem cells that secrete anti-inflammatory cytokines and growth factors while the hyaluronic acid component provides a scaffold for cell delivery and tissue integration. The combination works to modulate the immune response, reduce fibrosis, and promote regeneration of damaged tissue through multiple paracrine mechanisms rather than direct cell differentiation.","oneSentence":"Rexlemestrocel-L is an allogeneic mesenchymal stem cell therapy combined with hyaluronic acid that promotes tissue repair and reduces inflammation through paracrine signaling and immunomodulation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:54.884Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Knee osteoarthritis"},{"name":"Tendon and ligament injuries"}]},"trialDetails":[{"nctId":"NCT06325566","phase":"PHASE3","title":"Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain","status":"RECRUITING","sponsor":"Mesoblast, Ltd.","startDate":"2024-07-03","conditions":"Degenerative Disc Disease","enrollment":300},{"nctId":"NCT02412735","phase":"PHASE3","title":"Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain","status":"COMPLETED","sponsor":"Mesoblast, Ltd.","startDate":"2015-03-06","conditions":"Degenerative Disc Disease","enrollment":404}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Rexlemestrocel-L + HA Mixture","genericName":"Rexlemestrocel-L + HA Mixture","companyName":"Mesoblast, Ltd.","companyId":"mesoblast-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rexlemestrocel-L + HA mixture is being studied for its efficacy and safety in treating moderate to severe chronic low back pain associated with degenerative disc disease. This mixture is being compared to Rexlemestrocel-L alone and saline in a randomized, double-blind, controlled study.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}